AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|

21.9 C

New York

Thursday, June 25, 2026

Global Times: Xi calls for solid measures to modernize agriculture, rural areas

Taipei AI Companies Head to NextRise 2026, Strengthening Asia’s Hub for Enterprise AI Collaboration

Digital Health Market Size to Reach USD 1,830.4 Billion by 2033, Driven by Rising Adoption of Telehealth, mHealth, AI-Based Solutions, and Connected Healthcare Technologies:...

Tag: therapy

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 18, 2025 /PRNewswire/ -- The global Sleep Apnea Devices Market, valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025...

PEN America Acquires OnlineSOS, Expanding Commitment to Digital Safety and Free Expression

NEW YORK, July 18, 2025 /PRNewswire/ -- In a strategic move underscoring their shared commitment to combating online abuse, PEN America, a leading advocate...

Telia Lietuva results for 6 months of 2025

The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for 6 months’ period ended 30 June 2025.

Energy Fuels Now Producing Heavy Rare Earth Element Oxides

Energy Fuels has commenced producing heavy rare earth element oxides at its White Mesa Mill at pilot scale, and could be in a position...

Energy Fuels Now Producing Heavy Rare Earth Element Oxides

Energy Fuels has commenced producing heavy rare earth element oxides at its White Mesa Mill at pilot scale, and could be in a position...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

The evolving peanut allergy treatment market landscape features clinical trials led by DBV Technologies (Viaskin Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abello (Sublingual...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsTherapy

Global Times: Xi calls for solid measures to modernize agriculture, rural areas

Taipei AI Companies Head to NextRise 2026, Strengthening Asia’s Hub for Enterprise AI Collaboration

Digital Health Market Size to Reach USD 1,830.4 Billion by 2033, Driven by Rising Adoption of Telehealth, mHealth, AI-Based Solutions, and Connected Healthcare Technologies:...

Tag: therapy

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

Sleep Apnea Devices Market worth $11.6 billion by 2032 with 7.6% CAGR | MarketsandMarkets™

PEN America Acquires OnlineSOS, Expanding Commitment to Digital Safety and Free Expression

Telia Lietuva results for 6 months of 2025

Energy Fuels Now Producing Heavy Rare Earth Element Oxides

Energy Fuels Now Producing Heavy Rare Earth Element Oxides

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards

Peanut Allergy Market Set to Grow at a 16% CAGR During the Study Period (2020-2034) Owing to Current Usage of Epinephrine, Anticipated Usage of...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us